DCM
SYRE icon

Driehaus Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Driehaus Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$249M Buy
2,799,166
+8,381
+0.3% +$612K 1.44% 6
2026
Q1 		$141M Sell
2,790,785
-91,635
-3% -$3.45M 1.03% 14
2025
Q4 		$94.4M Buy
2,882,420
+822,045
+40% +$21.5M 0.64% 38
2025
Q3 		$34.5M Sell
2,060,375
-25,215
-1% -$411K 0.25% 134
2025
Q2 		$31.2M Sell
2,085,590
-631,722
-23% -$9.35M 0.25% 131
2025
Q1 		$43.8M Sell
2,717,312
-86,343
-3% -$1.8M 0.42% 71
2024
Q4 		$65.3M Buy
2,803,655
+2,116,575
+308% +$62.1M 0.54% 52
2024
Q3 		$20.2M Hold
687,080
– – 0.17% 168
2024
Q2 		$16.2M Hold
687,080
– – 0.16% 175
2024
Q1 		$26.1M Sell
687,080
-84,822
-11% -$2.46M 0.26% 113
2023
Q4 		$16.6M Sell
771,902
-28,951
-4% -$399K 0.2% 169
2023
Q3 		$9.81M Buy
800,853
+615,119
+331% +$8.13M 0.13% 211
2023
Q2 		$2.09M Buy
+185,734
New +$881K 0.03% 299
2021
Q2 		– Sell
-7,000
Closed -$1.39M – 514
2021
Q1 		$1.39M Sell
7,000
-9,651
-58% -$1.85M 0.02% 339
2020
Q4 		$3.28M Sell
16,651
-236
-1% -$48.9K 0.05% 272
2020
Q3 		$2.99M Sell
16,887
-301
-2% -$55.7K 0.06% 239
2020
Q2 		$3.98M Buy
+17,188
New +$3.27M 0.1% 214

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Driehaus Capital Management's SYRE Position: Q2 2026 in Review

Driehaus Capital Management increased its Spyre Therapeutics (SYRE) stake by 0.3% in Q2 2026, buying an estimated $612K and bringing the position to 2,799,166 shares worth $249M. The position accounts for 1.44% of the portfolio, ranked #6.

Driehaus Capital Management first reported a position in SYRE in Q2 2020 and has held it in 17 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Driehaus Capital Management held 2,799,166 shares of Spyre Therapeutics worth $249M as of Q2 2026.
  • Driehaus Capital Management bought 8,381 Spyre Therapeutics shares in Q2 2026, an estimated $612K.
  • Spyre Therapeutics made up 1.44% of Driehaus Capital Management's portfolio in Q2 2026, its #6 holding.
  • Driehaus Capital Management first reported a position in Spyre Therapeutics in Q2 2020 and has held it in 17 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.